KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biocryst Pharmaceuticals (BCRX) EBIT Margin (2023 - 2025)

Biocryst Pharmaceuticals (BCRX) has disclosed EBIT Margin for 9 consecutive years, with 64.05% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBIT Margin rose 6747.0% year-over-year to 64.05%, compared with a TTM value of 38.98% through Dec 2025, up 3954.0%, and an annual FY2025 reading of 38.98%, up 3954.0% over the prior year.
  • EBIT Margin was 64.05% for Q4 2025 at Biocryst Pharmaceuticals, up from 18.56% in the prior quarter.
  • Across five years, EBIT Margin topped out at 64.05% in Q4 2025 and bottomed at 28.31% in Q4 2023.
  • Average EBIT Margin over 3 years is 9.18%, with a median of 8.01% recorded in 2024.
  • Peak annual rise in EBIT Margin hit 6747bps in 2025, while the deepest fall reached 1022bps in 2025.
  • Year by year, EBIT Margin stood at 28.31% in 2023, then skyrocketed by 88bps to 3.43% in 2024, then surged by 1969bps to 64.05% in 2025.
  • Business Quant data shows EBIT Margin for BCRX at 64.05% in Q4 2025, 18.56% in Q3 2025, and 18.23% in Q2 2025.